Royalty Pharma plc (NASDAQ:RPRX) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $41.67.

Several equities analysts have commented on RPRX shares. Citigroup cut their price objective on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday. StockNews.com lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Monday. The Goldman Sachs Group raised their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a research report on Wednesday, August 14th. Finally, Morgan Stanley raised their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, July 11th.

Royalty Pharma Stock Performance

NASDAQ RPRX traded down $0.11 on Tuesday, reaching $27.15. 1,832,238 shares of the stock were exchanged, compared to its average volume of 2,578,422. The company's 50-day simple moving average is $28.02 and its two-hundred day simple moving average is $27.59. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $16.22 billion, a PE ratio of 20.34, a PEG ratio of 3.97 and a beta of 0.46. Royalty Pharma has a one year low of $25.20 and a one year high of $31.66.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The business had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. During the same period in the previous year, the business earned $0.85 earnings per share. Analysts expect that Royalty Pharma will post 4.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a dividend of $0.21 per share. The ex-dividend date is Friday, November 15th. This represents a $0.84 annualized dividend and a yield of 3.09%. Royalty Pharma's dividend payout ratio (DPR) is presently 62.69%.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in RPRX. Versant Capital Management Inc raised its holdings in Royalty Pharma by 5,215.0% in the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,043 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 943 shares in the last quarter. Gladius Capital Management LP purchased a new stake in Royalty Pharma during the second quarter valued at approximately $32,000. Fidelis Capital Partners LLC acquired a new stake in Royalty Pharma in the first quarter valued at approximately $46,000. Finally, EverSource Wealth Advisors LLC grew its holdings in Royalty Pharma by 32.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 655 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.